Official Prescription Website | JELMYTO® (mitomycin) For …
JELMYTO may cause serious side effects, including: Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your …
DailyMed - JELMYTO- Mitomycin Kit
JELMYTO may cause serious side effects, including: Swelling and narrowing of the …
Videos Of Jelmyto (Mitomycin)
JELMYTO ® (mitomycin) for pyelocalyceal solution is indicated for the treatment of …
Mitomycin - National Cancer Institute
JELMYTO ® (mitomycin) for pyelocalyceal solution is indicated for the treatment of …
Mitomycin (Mutamycin, Mitomycin-C, Jelmyto®) | OncoLink
JELMYTO ® (mitomycin) for pyelocalyceal solution is indicated for the treatment of …
Jelmyto™ (mitomycin)
JELMYTO ® (mitomycin) for pyelocalyceal solution is indicated for the treatment of …
FDA Approves Jelmyto (Mitomycin Gel) For Urothelial Cancer
Advise patients that JELMYTO contains mitomycin which is a violet to blue color and may discolor urine following the instillation procedure. Advise patients to avoid contact with urine for at least six hours post-instillation. Advise patients to void sitting on a toilet, flush the toilet several times after use, and to wash hands, perineum or glans with soap and water after each …
CP.PHAR.495 Mitomycin For Pyelocalyceal Solution (Jelmyto)
01/09/2021 · About: Mitomycin (Mutamycin, Mitomycin-C, Jelmyto®) Mitomycin is an antitumor antibiotic that is made from a soil fungus called Streptomyces caespitosus. Mitomycin inhibits DNA synthesis by producing DNA cross-links which halt cell replication and eventually cause cell death. Since cancer cells, in general, divide faster and with less error-correcting …
NDC 72493-103 Jelmyto Mitomycin
Jelmyto™ (mitomycin) (Intra-pyelocalyceal) -E- Document Number: IC-0586 Last Review Date: 02/02/2021 Date of Origin: 02/02/2021 Dates Reviewed: 02/2021 I. Length of Authorization Coverage will be provided initially for three months and may be renewed one time only for 11 months (maximum total of 17 doses from initial and maintenance treatments). II. Dosing Limits …